Glenview Capital to push CVS Health to make changes - Wall Street Journal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
October 2, 2024 6:56 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $65.00 price target on CVS Health (NYSE: CVS).
The analyst comments "Latest Hypothetical SOTP Suggests Upside, But Variables Remain: In light of a recent Reuters report (here) noting that the CVS Board may be considering potential options to break up CVS retail and insurance businesses, we detail our latest SOTP analysis, including key assumptions below. CVS declined to... More
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
October 1, 2024 6:28 AM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating on CVS Health (NYSE: CVS).
The analyst comments "Bottom Line: Following our initial note highlighting the potential of CVS evaluating strategic alternatives including a break-up of the company (Initial CVS note; WSJ report) we wanted to include some quick views on the potential plusses and potential minuses of a breakup. This isn't meant to be comprehensive and is intentionally short form given the fluidity of the reported situation. But we thought it was important to highlight how this... More
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
October 1, 2024 5:54 AM EDTEvercore ISI analyst Elizabeth Anderson reiterated an Outperform rating and $62.00 price target on CVS Health (NYSE: CVS).
The analyst comments "What happened? After the market close today, Reuters reported that CVS is exploring options, including a potential break-up of the company to... More
